MM-398 (Nanoliposomal Irinotecan, Nal-IRI)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MM-398 (Nanoliposomal Irinotecan, Nal-IRI), covering 2019-10-28 to 2019-10-28. Get the full timeline:
Most recent: Clinical Trial Update: MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment [Phase 1]